NSE · SUNPHARMA.NS
Sun Pharmaceutical Industries Limited
₹1,777.70+₹16.70 (+0.95%)
Sun Pharmaceutical Industries Limited’s quoted price sits in the lower half of its reported 52-week range, 13.15% below the high.
Loading market information…
NSE · VIMTALABS.NS · INR
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 09:59 AM UTC. Cached market data; not a live quote.
One-year closing-price history · INR. Historical prices are not a forecast.
Vimta Labs Limited’s quoted price sits in the lower half of its reported 52-week range, 33.93% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Vimta Labs Limited’s forward annual dividend is ₹2.00 per share, paid annual. The forward yield is 0.41% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Vimta Labs Limited’s next earnings report is currently expected on Oct 30, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Vimta Labs Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Vimta Labs Limited provides specialized contract research and analytical testing services, operating both within India and internationally. Their extensive offerings encompass general laboratory analyses, comprehensive food and water quality testing, support for preclinical and clinical research, detailed structural and functional assessments of biological molecules, environmental impact studies, and clinical diagnostic reference laboratory capabilities. The company serves a wide array of industries, including pharmaceuticals, biopharmaceuticals, food production, consumer goods, electronics, electrical equipment, agrochemicals, healthcare, medical devices, and many more. Established in 1984, Vimta Labs Limited is headquartered in Hyderabad, India.
Latest available per-share figures in INR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 10:50 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Nov 8, 2024 |
| ₹3.44 |
| ₹847.42M |
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
₹1,777.70+₹16.70 (+0.95%)
Sun Pharmaceutical Industries Limited’s quoted price sits in the lower half of its reported 52-week range, 13.15% below the high.
₹9,780.00+₹116.00 (+1.2%)
Divi's Laboratories Limited’s quoted price sits in the upper half of its reported 52-week range, 0.86% below the high.
₹4,613.40+₹33.40 (+0.73%)
Torrent Pharmaceuticals Limited’s quoted price sits in the upper half of its reported 52-week range, 12.13% below the high.
₹178.99-₹5.94 (-3.21%)
IOL Chemicals and Pharmaceuticals Limited’s quoted price sits in the upper half of its reported 52-week range, 20.09% below the high.
₹413.00-₹5.80 (-1.38%)
Gufic Biosciences Limited’s quoted price sits in the upper half of its reported 52-week range, 11.71% below the high.
₹486.25-₹18.70 (-3.7%)
Unichem Laboratories Limited’s quoted price sits in the upper half of its reported 52-week range, 29.24% below the high.
₹208.26+₹3.86 (+1.89%)
Hikal Limited’s quoted price sits in the upper half of its reported 52-week range, 20.21% below the high.
₹506.00+₹8.05 (+1.62%)
Krsnaa Diagnostics Limited’s quoted price sits in the lower half of its reported 52-week range, 39.62% below the high.
